Receptors and effects of gut hormones in three osteoblastic cell lines

BMC Physiology

Volumn 11, Issue 1, 2011, Pages

  Pacheco Pantoja, Elda L ^a   Ranganath, Lakshminarayan R ^b   Gallagher, James A ^c   Wilson, Peter Jm ^c   Fraser, William D ^c  

^a Universidad del Mayab   (Mexico)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GASTROINTESTINAL HORMONE; GHRELIN; GHRELIN RECEPTOR; GLP 2 RECEPTOR; GLP-2 RECEPTOR; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; HORMONE RECEPTOR; OBESTATIN, HUMAN; OSTEOCALCIN; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N TERMINAL PEPTIDE; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE;

ARTICLE; BIOSYNTHESIS; CELL LINE; DRUG EFFECT; HUMAN; METABOLISM; OSTEOBLAST;

ALKALINE PHOSPHATASE; CELL LINE; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; GHRELIN; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; HUMANS; OSTEOBLASTS; OSTEOCALCIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GHRELIN; RECEPTORS, GLUCAGON;

EID: 79960883269     PISSN: None     EISSN: 14726793     Source Type: Journal    
DOI: 10.1186/1472-6793-11-12     Document Type: Article

References (55)

1. Dietary restriction of energy and calcium alters bone turnover and density in younger and older female rats. Talbott SM, Rothkopf MM, Shapses SA, J Nut 1998 128 3 640 645 (Pubitemid 28188364)
2. Interrelationship between bone turnover markers and dietary calcium intake in pregnant women: a longitudinal study. Zeni SN, Soler CRO, Lazzari A, Lápez L, Suarez M, Di Gregorio S, Somoza JI, de Portela ML, Bone 2003 33 4 606 613 10.1016/S8756-3282(03)00203-5 14555265 (Pubitemid 37222387)
3. Potential role of pancreatic and enteric hormones in regulating bone turnover. Clowes JA, Khosla S, Eastell R, J Bone Miner Res 2005 20 9 1497 1506 10.1359/JBMR.050524 16059621 (Pubitemid 41243538)
4. The hormonal regulation of food intake, digestion, and absorption. Nicholl CG, Polak JM, Bloom SR, Annu Rev Nutr 1985 5 213 239 10.1146/annurev.nu.05.070185.001241 2411280
5. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Bollag RJ, Zhong Q, Ding KH, Phillips P, Zhong L, Qin F, Cranford J, Mulloy AL, Cameron R, Isales CM, Mol Cell Endocrinol 2001 177 1-2 35 41 10.1016/S0303-7207(01)00405-1 11377818 (Pubitemid 32506803)
6. Entero-insular axis. Unger RH, Eisentraut AM, Arch Intern Med 1969 123 3 261 266 10.1001/archinte.123.3.261 4885674
7. Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. Bollag RJ, Zhong Q, Phillips P, Min L, Zhong L, Cameron R, Mulloy AL, Rasmussen H, Qin F, Ding KH, Isales CM, Endocrinology 2000 141 3 1228 1235 10.1210/en.141.3.1228 10698200 (Pubitemid 32260466)
8. Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. Tsukiyama K, Yamada Y, Yamada C, Harada N, Kawasaki Y, Ogura M, Bessho K, Li M, Amizuka N, Sato M, Udagawa N, Takahashi N, Tanaka K, Oiso Y, Seino Y, Mol Endocrinol 2006 20 7 1644 1651 16469773 (Pubitemid 43967571)
9. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Xie D, Cheng H, Hamrick M, Zhong Q, Ding KH, Correa D, Williams S, Mulloy A, Bollag W, Bollag RJ, Runner RR, McPherson JC, Insogna K, Isales CM, Bone 2005 37 6 759 769 10.1016/j.bone.2005.06.021 16219496 (Pubitemid 41773485)
10. Effects of glucose-dependent insulinotropic peptide on osteoclast function. Zhong Q, Itokawa T, Sridhar S, Ding KH, Xie D, Kang B, Bollag WB, Bollag RJ, Hamrick M, Insogna K, Isales CM, Am J Physiol Endocrinol Metab 2007 292 2 543 E548 17003233
11. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Nuche-Berenguer B, Moreno P, Esbrit P, Dapía S, Caeiro JR, Cancelas J, Haro-Mora JJ, Villanueva- Pẽacarrillo ML, Calcif Tissue Int 2009 84 6 453 461 10.1007/s00223-009- 9220-3 19219381
12. The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N, Endocrinology 2008 149 2 574 579 18039776 (Pubitemid 351159357)
13. Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. Nuche-Berenguer B, Portal-Nú̃ez S, Moreno P, González N, Acitores A, Lápez-Herradán A, Esbrit P, Valverde I, Villanueva- Pẽacarrillo ML, J Cell Physiol 2010 225 2 585 592 10.1002/jcp.22243 20506394
14. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF, Endocrinology 2002 143 8 3152 3161 10.1210/en.143.8.3152 12130581 (Pubitemid 34809888)
15. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ, J Biol Chem 2003 278 1 471 478 12409292 (Pubitemid 36043598)
16. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Haderslev KV, Jeppesen PB, Hartmann B, Thulesen J, Sorensen HA, Graff J, Hansen BS, Tofteng F, Poulsen SS, Madsen JL, Holst JJ, Staun M, Mortensen PB, Scand J Gastroenterol 2002 37 4 392 398 10.1080/003655202317316006 11989828 (Pubitemid 34274321)
17. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Henriksen DB, Alexandersen P, Byrjalsen I, Hartmann B, Bone HG, Christiansen C, Holst JJ, Bone 2004 34 1 140 147 10.1016/j.bone.2003.09.009 14751571 (Pubitemid 38142442)
18. Ghrelin: structure and function. Kojima M, Kangawa K, Physiol Rev 2005 85 2 495 522 10.1152/physrev.00012.2004 15788704 (Pubitemid 40404635)
19. Ghrelin regulates proliferation and differentiation of osteoblastic cells. Maccarinelli G, Sibilia V, Torsello A, Raimondo F, Pitto M, Giustina A, Netti C, Cocchi D, J Endocrinol 2005 184 1 249 256 10.1677/joe.1.05837 15642801 (Pubitemid 40207579)
20. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, Han BH, Kim MS, Shin CS, Kim SY, Bone 2005 37 3 359 369 10.1016/j.bone.2005.04.020 15978880 (Pubitemid 41160494)
21. Ghrelin directly regulates bone formation. Fukushima N, Hanada R, Teranishi H, Fukue Y, Tachibana T, Ishikawa H, Takeda S, Takeuchi Y, Fukumoto S, Kanagawa K, Nagata K, Kojima M, J Bone Miner Res 2005 20 5 790 798 15824852 (Pubitemid 40571636)
22. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, Klein C, Hsueh AJ, Science 2005 310 5750 996 999 10.1126/science.1117255 16284174 (Pubitemid 41611907)
23. Role of obestatin on growth hormone secretion: An in vitro approach. Pazos Y, Alvarez CJP, Camĩa JP, Al-Massadi O, Seoane LM, Casanueva FF, Biochem Biophys Res Commun 2009 390 4 1377 1381 10.1016/j.bbrc.2009.10.163 19895783
24. GPR39 signaling is stimulated by zinc ions but not by obestatin. Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, Gerlach LO, Storjohann L, Stidsen CE, Jones R, Beck-Sickinger AG, Schwarts TW, Endocrinology 2007 148 1 13 20 16959833 (Pubitemid 46021433)
25. Obestatin does not activate orphan G protein-coupled receptor GPR39. Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W, Biochem Biophys Res Commun 2006 351 1 21 25 10.1016/j.bbrc.2006.09.141 17054911 (Pubitemid 44740415)
26. Obestatin induction of early-response gene expression in gastrointestinal and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Zhang JV, Jahr H, Luo CW, Klein C, Van Kolen K, Ver Donck L, De A, Baart E, Li J, Moechars D, Hsueh AJ, Mol Endocrinol 2008 22 6 1464 1475 10.1210/me.2007-0569 18337590 (Pubitemid 351787005)
27. Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype? Clover J, Gowen M, Bone 1994 15 6 585 591 10.1016/8756-3282(94)90305-0 7873286 (Pubitemid 24332649)
28. Human interferon: mass production in a newly established cell line, MG-63. Billiau A, Edy VG, Heremans H, Van Damme J, Desmyter J, Georgiades JA, De Somer P, Antimicrob Agents Chemother 1977 12 1 11 15 883813 (Pubitemid 8143077)
29. Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Rodan SB, Imai Y, Thiede MA, Wesolowski G, Thompson D, Bar-Shavit Z, Shull S, Mann K, Rodan GA, Cancer Res 1987 47 18 4961 4966 3040234 (Pubitemid 17143047)
30. Statistical significance of quantitative PCR. Karlen Y, McNair A, Perseguers S, Mazza C, Mermod N, BMC Bioinformatics 2007 8 131 146 10.1186/1471-2105-8-131 17445280 (Pubitemid 46767747)
31. Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Bellows CG, Reimers SM, Heersche JN, Cell Tissue Res 1999 297 2 249 259 10.1007/s004410051353 10470495 (Pubitemid 29366470)
32. The roles of annexins and alkaline phosphatase in mineralization process. Balcerzak M, Hamade E, Zhang L, Pikula S, Azzar G, Radisson J, Bandorowicz-Pikula J, Buchet R, Acta Biochim Pol 2003 50 4 1019 1038 14739992 (Pubitemid 38608833)
33. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. Thomas GP, Baker SU, Eisman JA, Gardiner EM, J Endocrinol 2001 170 2 451 460 10.1677/joe.0.1700451 11479141 (Pubitemid 32771446)
34. A rapid, simple method for detecting PCR failure. Pallen MJ, Puckey LH, Wren BW, PCR Methods Appl 1992 2 1 91 92 1490181
35. Quantitative RT-PCR. A review of current methodologies. Joyce C, Methods Mol Biol 2002 193 83 92 12325527
36. GLP-2 is a key player in the regulation of bone turnover: new prophylaxis? [abstract]. Henriksen DB, Alexandersen P, Andersen TL, Byrjalsen I, Henriksen EG, Hartmann B, Christiansen C, Holst JJ, J Bone Miner Res 2003 18 Suppl 2 54
37. Evidence that gut hormone receptors are expressed on circulating peripheral blood cells [abstract]. Clowes JA, Xiao J, Eastell R, Khosla S, J Bone Miner Res 2005 20 Ssuppl 1 U382
38. Role of gastrointestinal hormones in postprandial reduction of bone resorption. Henriksen DB, Alexandersen P, Bjarnason NH, Vilsbøll T, Hartmann B, Henriksen EE, Byrjalsen I, Krarup T, Holst JJ, Christiansen C, J Bone Miner Res 2003 18 12 2180 2189 10.1359/jbmr.2003.18.12.2180 14672353 (Pubitemid 37463311)
39. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C, Bone 2009 45 5 833 842 10.1016/j.bone.2009.07.008 19631303
40. Altered gastrointestinal and metabolic function in the GPR39-obestatin receptor-knockout mouse. Moechars D, Depoortere I, Moreaux B, de Smet B, Goris I, Hoskens L, Daneels G, Kass S, Ver Donck L, Peeters T, Coulie B, Gastroenterology 2006 131 4 1131 1141 10.1053/j.gastro.2006.07.009 17030183 (Pubitemid 44498686)
41. Normal food intake and body weight in mice lacking the G protein-coupled receptor GPR39. Tremblay F, Perreault M, Klaman LD, Tobin JF, Smith E, Gimeno RE, Endocrinology 2007 148 2 501 506 17095592 (Pubitemid 46143155)
42. Is GPR39 the natural receptor of obestatin? Dong XY, He JM, Tang SQ, Li HY, Jiang QY, Zou XT, Peptides 2009 30 2 431 438 10.1016/j.peptides.2008.09.022 18977259
43. Meal-frequency effects on plasma hormone concentrations and cholesterol synthesis in humans. Jones PJ, Leitch CA, Pederson RA, Am J Clin Nutr 1993 57 6 868 874 8503355 (Pubitemid 23156708)
44. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S, J Clin Endocrinol Metab 2002 87 1 240 244 10.1210/jc.87.1.240 11788653 (Pubitemid 34084697)
45. Rapid bone loss is associated with increased levels of biochemical markers. Ross PD, Knowlton W, J Bone Miner Res 1998 13 2 297 302 10.1359/jbmr.1998.13.2.297 9495524 (Pubitemid 28082387)
46. Use of bone alkaline phosphatase to monitor alendronate therapy in individual postmenopausal osteoporotic women. Kress BC, Mizrahi IA, Armour KW, Marcus R, Emkey RD, Santora AC, Clin Chem 1999 45 7 1009 1017 10388477 (Pubitemid 29340538)
47. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH, Bone 2010 46 4 935 939 10.1016/j.bone.2009.12.032 20060081
48. Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Xie D, Zhong Q, Ding KH, Cheng H, Williams S, Correa D, Bollag WB, Bollag RJ, Insogna K, Troiano N, Coady C, Hamrick M, Isales CM, Bone 2007 40 5 1352 1360 10.1016/j.bone.2007.01.007 17321229 (Pubitemid 46566429)
49. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. Ding KH, Shi XM, Zhong Q, Kang B, Xie D, Bollag WB, Bollag RJ, Hill W, Washington W, Mi QS, Insogna K, Chutkan N, Hamrick M, Isales CM, J Bone Miner Res 2008 23 4 536 543 18072880 (Pubitemid 351501894)
50. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C, Bone 2007 40 3 723 729 10.1016/j.bone.2006.09.025 17081815 (Pubitemid 46201945)
51. Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects. Huda MSB, Durham BH, Wong SP, Dovey TM, McCulloch P, Kerrigan D, Pinkney JH, Fraser WD, Wilding JP, Bone 2007 41 3 406 413 10.1016/j.bone.2007.05.006 17613297 (Pubitemid 47199153)
52. Unlike ghrelin, obestatin does not exert any relevant activity in chondrocytes. Lago R, Gomez R, Dieguez C, Gomez-Reino JJ, Lago F, Gualillo O, Ann Rheum Dis 2007 66 1399 1400 10.1136/ard.2006.068155 17881664 (Pubitemid 47492491)
53. Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, Nano R, Annunziata M, Campiglia P, Arnoletti E, Ghè C, Volante M, Papotti M, Muccioli G, Ghigo E, Diabetes 2008 57 4 967 979 10.2337/db07-1104 18162507
54. Lack of effect of the ghrelin gene-derived peptide obestatin on cardiomyocyte viability and metabolism. Iglesias MJ, Salgado A, Pĩeiro R, Rodĩo BK, Otero MF, Grigorian L, Gallego R, Diéguez C, Gualillo O, González-Juanatey JR, Lago F, J Endocrinol Invest 2007 30 6 470 476 17646721 (Pubitemid 47496456)
55. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Ferguson SS, Pharmacol Rev 2001 53 1 1 24 11171937 (Pubitemid 32173106)